Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective studyDongbo Chen, Liyang Zhu, Yichun Wang et al.|Scientific Reports|2023Cited by 3
Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessmentDongbo Chen, Kang Mei, Yichun Wang et al.|Neoplasma|2023Cited by 3
Camrelizumab/apatinib vs. sorafenib as therapy for primary liver cancer: a retrospective study of a single CenterDongbo Chen, Liyang Zhu, Yichun Wang et al.|Research Square|2023Cited by 0